| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_707fed4a1a60fa61a1abd576112d5c64 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G09B23-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G09B23-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 |
| filingDate |
2017-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5aee9ccae65b4418136d2b2da79737e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a68aa9cdda26dc45669f11533ca0c0bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc8ec8efd31959bdd4c6f27e12ec2098
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5f37bab2b48b9b945178a3d01f9ec2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cce5db89e87aa61b5f2c62108ec3b2ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97653cc9514732a2c018a5b1c9b57dab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfab6c25cb5ce9a4d3bbde986cf8dde4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d20f88447e72ec733a9de21e7b9760b |
| publicationDate |
2018-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2661704-C1 |
| titleOfInvention |
Method for achieving antimetastatic effect in experiment |
| abstract |
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to experimental research in oncology, and can be used in development of methods for achieving antimetastatic effect. Method comprises paratamoral administration of immunomodulators to the tumor-bearing mice with melanoma B16 10 days after the transplantation. To do this alternately every other day add 0.3 ml of 150 IU Roncoleukin and 0.3 ml of 150 IU Ingarone for 8 days.EFFECT: method provides complete inhibition of metastasis as compared to control group and also inhibits tumor growth.1 cl, 1 tbl |
| priorityDate |
2017-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |